This report provides comprehensive information on the therapeutic development for Otitis Media, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Otitis Media and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Otitis Media Overview
- Therapeutics Development
- Pipeline Products for Otitis Media - Overview
- Pipeline Products for Otitis Media - Comparative Analysis
- Otitis Media - Therapeutics under Development by Companies
- Otitis Media - Therapeutics under Investigation by Universities/Institutes
- Otitis Media Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Otitis Media - Products under Development by Companies
- Otitis Media - Products under Investigation by Universities/Institutes
- Otitis Media - Companies Involved in Therapeutics Development
- Cellceutix Corporation
- ContraFect Corporation
- GlaxoSmithKline Plc
- Lee's Pharmaceutical Holdings Limited
- Madam Therapeutics B.V.
- Merck & Co., Inc.
- MerLion Pharmaceuticals Pte Ltd
- Oticpharma Ltd
- Otonomy, Inc.
- Yuhan Corporation
For more information about this drug pipelines visit http://www.researchandmarkets.com/research/f76zkp/otitis_media
Related Topics: Immune Disorders Drugs